Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

SURMOUNT-1

Eli Lilly · Phase 3 · Completed · Enrollment 2539

NCT04184622

Y axis: Change in body weight from baseline, %

0-5-10-15-20-250481216202436486072Placebo, week 72, -3.1%5 mg Tirzepatide, week 72, -15%10 mg Tirzepatide, week 72, -19.5%15 mg Tirzepatide, week 72, -20.9%

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Placebo, one timepoint
  • 5 mg Tirzepatide, one timepoint
  • 10 mg Tirzepatide, one timepoint
  • 15 mg Tirzepatide, one timepoint
  • Placebo: week 72 -3.1%
  • 5 mg Tirzepatide: week 72 -15%
  • 10 mg Tirzepatide: week 72 -19.5%
  • 15 mg Tirzepatide: week 72 -20.9%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.